Literature DB >> 25646111

The roles of patents and research and development incentives in biopharmaceutical innovation.

Henry G Grabowski1, Joseph A DiMasi2, Genia Long3.   

Abstract

Patents and other forms of intellectual property protection play essential roles in encouraging innovation in biopharmaceuticals. As part of the "21st Century Cures" initiative, Congress is reviewing the policy mechanisms designed to accelerate the discovery, development, and delivery of new treatments. Debate continues about how best to balance patent and intellectual property incentives to encourage innovation, on the one hand, and generic utilization and price competition, on the other hand. We review the current framework for accomplishing these dual objectives and the important role of patents and regulatory exclusivity (together, the patent-based system), given the lengthy, costly, and risky biopharmaceutical research and development process. We summarize existing targeted incentives, such as for orphan drugs and neglected diseases, and we consider the pros and cons of proposed voluntary or mandatory alternatives to the patent-based system, such as prizes and government research and development contracting. We conclude that patents and regulatory exclusivity provisions are likely to remain the core approach to providing incentives for biopharmaceutical research and development. However, prizes and other voluntary supplements could play a useful role in addressing unmet needs and gaps in specific circumstances. Project HOPE—The People-to-People Health Foundation, Inc.

Keywords:  Biotechnology; Legal/Regulatory Issues; Pharmaceuticals

Mesh:

Year:  2015        PMID: 25646111     DOI: 10.1377/hlthaff.2014.1047

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  12 in total

1.  Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.

Authors:  Clemens Stockklausner; Anette Lampert; Georg F Hoffmann; Markus Ries
Journal:  Oncologist       Date:  2016-03-28

2.  Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review.

Authors:  Aaron S Long; Audrey D Zhang; Caitlin E Meyer; Alexander C Egilman; Joseph S Ross; Joshua D Wallach
Journal:  JAMA Netw Open       Date:  2021-05-03

3.  Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

Authors:  Rositsa Koleva-Kolarova; James Buchanan; Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; Maureen Rutten-van Mölken; László Szilberhorn; Tamás Zelei; Balázs Nagy; Sarah Wordsworth; Apostolos Tsiachristas
Journal:  Appl Health Econ Health Policy       Date:  2022-04-04       Impact factor: 3.686

4.  Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?

Authors:  R Rodriguez-Monguio; T Spargo; E Seoane-Vazquez
Journal:  Orphanet J Rare Dis       Date:  2017-01-05       Impact factor: 4.123

5.  From Gutenberg to Open Science: An Unfulfilled Odyssey.

Authors:  Chris R Triggle; David J Triggle
Journal:  Drug Dev Res       Date:  2016-10-21       Impact factor: 4.360

Review 6.  Financing Drug Innovation in the US: Current Framework and Emerging Challenges.

Authors:  David Cutler; Noam Kirson; Genia Long
Journal:  Pharmacoeconomics       Date:  2020-09       Impact factor: 4.981

7.  The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.

Authors:  Marion Motari; Jean-Baptiste Nikiema; Ossy M J Kasilo; Stanislav Kniazkov; Andre Loua; Aissatou Sougou; Prosper Tumusiime
Journal:  BMC Public Health       Date:  2021-03-11       Impact factor: 3.295

8.  Longitudinal study of the impact of three major regulations on the Korean pharmaceutical industry in the last 30 years.

Authors:  Seung In Um; Uy Dong Sohn; Sun-Young Jung; Seung-Hun You; Changone Kim; Sora Lee; Heesang Lee
Journal:  Health Res Policy Syst       Date:  2022-01-06

9.  The Contrasting Perceptions and the Cause Regarding Patenting Technologies Between Academic Medical Researchers and Pharmaceutical Companies Based in Japan.

Authors:  Kazunari Sugimitsu; Yoshinobu Manome
Journal:  J Multidiscip Healthc       Date:  2021-07-12

10.  Branded prescription drug spending: a framework to evaluate policy options.

Authors:  Jeromie Ballreich; G Caleb Alexander; Mariana Socal; Taruja Karmarkar; Gerard Anderson
Journal:  J Pharm Policy Pract       Date:  2017-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.